modelTapentadol
Extends from Pharmacolibrary.Drugs.ATC.N.N02AX06.
Information
| name: | Tapentadol | |
| ATC code: | N02AX06 | route: | oral |
| compartments: | 1 | |
| dosage: | 100 | mg |
| volume of distribution: | 540 | L |
| clearance: | 1530 | mL/min |
| other parameters in model implementation | ||
Tapentadol is a centrally acting opioid analgesic used for the management of moderate to severe acute pain and chronic pain. It is a mu-opioid receptor agonist and a norepinephrine reuptake inhibitor. Tapentadol is approved and in use today for pain management in various countries.
Pharmacokinetics
Pharmacokinetic parameters as reported in healthy adult volunteers following oral immediate-release tapentadol.
References
Khalil, F, et al., & Freijer, J (2020). Population Pharmacokinetics of Tapentadol in Children from Birth to <18 Years Old. Journal of pain research 13 3107–3123. DOI:10.2147/JPR.S269549 PUBMED:https://pubmed.ncbi.nlm.nih.gov/33262645
Jończyk, R, et al., & Khalil, F (2022). Multiple Dose Pharmacokinetics of Tapentadol Oral Solution for the Treatment of Moderate to Severe Acute Pain in Children Aged 2 to <7 Years. Journal of pain research 15 3103–3114. DOI:10.2147/JPR.S364902 PUBMED:https://pubmed.ncbi.nlm.nih.gov/36203787
Xu, XS, et al., & Nandy, P (2010). Population pharmacokinetics of tapentadol immediate release (IR) in healthy subjects and patients with moderate or severe pain. Clinical pharmacokinetics 49(10) 671–682. DOI:10.2165/11535390-000000000-00000 PUBMED:https://pubmed.ncbi.nlm.nih.gov/20818833
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
| Pharmacolibrary.Types.TransferRate | ka (from PK_1C_enteral) | 0.016666666666666666 | first order absorption rate |
| Modelica.Units.SI.Time | Tlag (from PK_1C_enteral) | 600 | delay between oral administration and absorption (default 10min) |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)